The clinical promise of mRNA therapeutics and vaccines is clear, but their novelty also brings new challenges to the manufacturing process. Compared to monoclonal antibodies or viral vectors, cell-free mRNA production is faster. However, in vitro transcription, purification efficiency, and lipid nanoparticle (LNP)-mediated delivery each add process challenges.
In this presentation, we’ll discuss strategies and technologies for addressing these challenges to develop a robust, scalable, and integrated mRNA manufacturing process. We’ll also address the LNP step, insourcing vs outsourcing, and batch management.
